Javascript must be enabled to continue!
Prelox® for Improvement of Erectile Quality
View through CrossRef
Sexual desire typically persists when men grow older although their ability to attain and maintain erections sufficient to permit satisfactory sexual intercourse gradually declines. Decreasing erectile quality is a common age-related problem affecting the lives of both men and their partners. Lifestyle plays an important role in the onset of erectile quality problems, and timely improvements such as a healthier diet and exercise may significantly slow the progression to erectile dysfunction with increasing age. Essentially, all cardiovascular risk factors – including hypertension, dyslipidaemia, hyperglycaemia, obesity and cigarette smoking – impair endothelial function, which in turn directly translates into declining erectile function. In this regard a man’s penis does indeed represent a barometer indicating his cardiovascular health status. Once endothelial function has declined to a point where its restoration is not feasible, pharmacological interventions with phosphodiesterase-5 (PDE5) inhibitors may temporarily bypass physiological processes so that affected men may still enjoy sexual intercourse. A timely intervention that helps to restore endothelial function will have the advantage of preserving a man’s ability to spontaneously respond to sexual arousal. Prelox®, a patented complex formulation consisting of Pycnogenol® and L-arginine aspartate, has been demonstrated in four clinical trials to naturally restore healthy erectile quality in men presenting with moderate erectile problems. Pycnogenol, a key component of Prelox, was shown in human pharmacological studies to act as a catalyst on endothelial nitric oxide (NO) synthase for amplified synthesis of NO, the initial mediator for triggering an erection. Its combination with the enzyme’s substrate, L-arginine, synergistically increases synthesis of NO, the key component involved in vasodilatation for improved blood flow to engorge the penis. According to reviewed clinical trials, Prelox will help men with moderate erectile problems to regain healthy erectile function, greater confidence to initiate and sustain erections and more frequent morning erections. As a result of higher intercourse frequency, men taking Prelox developed significantly higher plasma testosterone values. Prelox is a safe, well-tolerated and efficacious treatment for mild to moderate cases of declining erectile quality.
Title: Prelox® for Improvement of Erectile Quality
Description:
Sexual desire typically persists when men grow older although their ability to attain and maintain erections sufficient to permit satisfactory sexual intercourse gradually declines.
Decreasing erectile quality is a common age-related problem affecting the lives of both men and their partners.
Lifestyle plays an important role in the onset of erectile quality problems, and timely improvements such as a healthier diet and exercise may significantly slow the progression to erectile dysfunction with increasing age.
Essentially, all cardiovascular risk factors – including hypertension, dyslipidaemia, hyperglycaemia, obesity and cigarette smoking – impair endothelial function, which in turn directly translates into declining erectile function.
In this regard a man’s penis does indeed represent a barometer indicating his cardiovascular health status.
Once endothelial function has declined to a point where its restoration is not feasible, pharmacological interventions with phosphodiesterase-5 (PDE5) inhibitors may temporarily bypass physiological processes so that affected men may still enjoy sexual intercourse.
A timely intervention that helps to restore endothelial function will have the advantage of preserving a man’s ability to spontaneously respond to sexual arousal.
Prelox®, a patented complex formulation consisting of Pycnogenol® and L-arginine aspartate, has been demonstrated in four clinical trials to naturally restore healthy erectile quality in men presenting with moderate erectile problems.
Pycnogenol, a key component of Prelox, was shown in human pharmacological studies to act as a catalyst on endothelial nitric oxide (NO) synthase for amplified synthesis of NO, the initial mediator for triggering an erection.
Its combination with the enzyme’s substrate, L-arginine, synergistically increases synthesis of NO, the key component involved in vasodilatation for improved blood flow to engorge the penis.
According to reviewed clinical trials, Prelox will help men with moderate erectile problems to regain healthy erectile function, greater confidence to initiate and sustain erections and more frequent morning erections.
As a result of higher intercourse frequency, men taking Prelox developed significantly higher plasma testosterone values.
Prelox is a safe, well-tolerated and efficacious treatment for mild to moderate cases of declining erectile quality.
Related Results
Prevalence and determinants of erectile dysfunction in Santos, southeastern Brazil
Prevalence and determinants of erectile dysfunction in Santos, southeastern Brazil
CONTEXT: Recent population-based surveys suggest that the prevalence of erectile dysfunction is between 30% and 56% among men over the age of 40. Most of these studies, however, ar...
Unraveling the intersection of sleep disorders and erectile dysfunction: Outcomes from two EPISONO editions
Unraveling the intersection of sleep disorders and erectile dysfunction: Outcomes from two EPISONO editions
AbstractBackgroundThere is growing interest in the relationship between sleep disorders and erectile dysfunction. We present the results from a 2015 follow‐up study in relation to ...
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis
Radical prostatectomy is the most commonly performed treatment option for localised prostate cancer. In the last decades the surgical technique has been improved and modified in or...
Erectile dysfunction in young men in Nairobi County, Kenya: A community-based study
Erectile dysfunction in young men in Nairobi County, Kenya: A community-based study
Abstract
Erectile dysfunction is commonly perceived as a condition of older men, yet increasing evidence suggests that it also affects younger populations. Data on ...
Erectile Dysfunction And Associated Factors Among Adult Hypertensive Patients Attending Outpatient Care At Public Hospitals in Harari Regional State,Eastern Ethiopia
Erectile Dysfunction And Associated Factors Among Adult Hypertensive Patients Attending Outpatient Care At Public Hospitals in Harari Regional State,Eastern Ethiopia
Abstract
Introduction. Sexual dysfunction is lack of sexual ideas or thoughts, diminished sexual interest or desire, and unresponsive sexual desire. Sexual dysfunctions is ...
Erectile Dysfunction and Associated Factors Among Adult Hypertensive Patients Attending Outpatient Care at Public Hospitals in Harari Regional State, Eastern Ethiopia
Erectile Dysfunction and Associated Factors Among Adult Hypertensive Patients Attending Outpatient Care at Public Hospitals in Harari Regional State, Eastern Ethiopia
<i>Introduction</i>. Sexual dysfunction is lack of sexual ideas or thoughts, diminished sexual interest or desire, and unresponsive sexual desire. Sexua...
Using Statistics and Data Mining Approaches to Analyze Male Sexual Behaviors and Use of Erectile Dysfunction Drugs Based on Large Questionnaire Data
Using Statistics and Data Mining Approaches to Analyze Male Sexual Behaviors and Use of Erectile Dysfunction Drugs Based on Large Questionnaire Data
The prevalence of erectile dysfunction (ED) has been extensively studied worldwide. Erectile dysfunction drugs has shown great efficacy in preventing male erectile dysfunction. In ...
Cardiovascular risk among men with and without erectile dysfunction: case-control study
Cardiovascular risk among men with and without erectile dysfunction: case-control study
Objective
There is growing evidence of a link between erectile dysfunction (ED), metabolic syndrome (MS) and cardiovascular disease (CVD). The study was to evalua...

